EXTON, Pa.--(BUSINESS WIRE)--Nov. 7, 2005--Othera Pharmaceuticals, Inc., a specialty pharmaceuticals company focused on treating eye disease, today announced that it has initiated a Phase 2 clinical trial of its lead compound, a topically administered eye drop, OT-551.
